Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

Discover how Pitavastatin, a cholesterol-lowering drug, shows promise as a treatment for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2 amplification, limiting the effectiveness of targeted therapies and contributing to its aggressive clinical behavior. As aberrant ...

Trodelvy showed fewer severe side effects and required fewer dose reductions or discontinuations compared to chemotherapy in TNBC patients. Common side effects, such as neutropenia and diarrhea, were ...

In what researchers are calling a potentially transformative development for breast cancer care, an experimental vaccine targeting triple-negative breast cancer (TNBC) has shown encouraging results in ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in many cases. However, some cancers, like triple-negative breast cancer (TNBC) ...

Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC patients. The study's primary endpoint, progression-free survival, favored ...

Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have ...